We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





IVD Market Exceeded USD 50 Billion in 2011

By LabMedica International staff writers
Posted on 18 Jul 2012
AACC 2012: A market research company reports that the world market for in vitro diagnostics (IVD) is estimated at USD 50.9 billion for 2011.

According to a report by the healthcare market research publisher, Kalorama Information (New York, NY, USA) growth in the IVD market is driven by an aging population, product innovations, and sales to emerging markets. More...
Kalorama revealed its findings as the industry meets and assesses its progress at the annual 2012 meeting of the American Association for Clinical Chemistry (AACC), which is being held in Los Angeles (CA, USA) from July 15-July 19, 2012.

The revenue estimate for 2011 includes all laboratory and hospital-based products, and over-the-counter (OTC) product sales. The report found that the IVD market has grown but it will be challenged with a sharp decline in pricing for diagnostic tests in Europe and consolidation in the US, which could lead to price erosion.

“A number of world events bode well for the future of medical devices: an aging worldwide population and demand for new hospitals in developing countries,” said Shara Rosen, Kalorama diagnostic analyst and author of the report. “Increasing numbers of people between the ages of 45 and 75 years in the industrialized world consume more healthcare services such as heart and cancer tests.”

Some of the total market growth expected in the coming years could derive from increased test usage in emerging countries. Significant growth is expected in Brazil, China, and India, which are investing in healthcare infrastructure and insurance coverage for a growing, more affluent middle class.

The new availability of choices, undoubtedly good for medical care, poses problems for the physician who must choose correctly from among the numerous new IVD products, and for payers to pay for new technologies that may still be unproven.

Some of the total market growth expected in the coming years could derive from increased test usage in emerging countries. Significant growth is expected in Brazil, China, and India, which are investing in healthcare infrastructure and insurance coverage for a growing, more affluent middle class.

“IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and growing demands for quality medical care,” remarked Shara Rosen.

Related Links:

Kalorama Information



New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.